[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/spikes/gap-cancers.ts","type":"changed","fields":[{"field":"openProblems","before":"[\"Indefinite BTKi therapy: cost, toxicity and resistance (BTK C481S).\", \"CXCR4-mutant disease responds slower and shallower.\", \"No approved therapy specific to IgM-related neuropathy.\", \"Transformation to DLBCL (5-10%...","after":"[\"Indefinite BTKi therapy: cost, toxicity and resistance (BTK C481S).\", \"CXCR4-mutant disease responds slower and shallower.\", \"No approved therapy specific to IgM-related neuropathy.\", \"Transformation to DLBCL (5-10%..."}]},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/spikes/gap-cancers.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"group"},{"field":"wikipedia"},{"field":"aka"},{"field":"burden"},{"field":"tldr"},{"field":"summary"},{"field":"subtypes"},{"field":"biomarkers"},{"field":"standardOfCare"},{"field":"stateOfArt"},{"field":"history"},{"field":"pipeline"},{"field":"openProblems"},{"field":"targets"},{"field":"technologies"},{"field":"drugs"},{"field":"companies"},{"field":"terms"},{"field":"links"},{"field":"tags"}]}]